Heterologous expression of human drug-metabolizing enzymes

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1234-1241

  Guengerich, F Peter ^b   Parikh, Asit ^c   Johnson, Eric F ^c   Richardson, Toby H ^c   Von Wachenfeldt, Claes ^c   Cosme, Jose ^c   Jung, Frank ^c   Strassburg, Christian P ^c   Manns, Michael P ^c   Tukey, Robert H ^c   Pritchard, Mike ^c   Fournel Gigleux, Sylvie ^a   Burchell, Brian ^c  

^a CNRS   (France)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; URIDINE DIPHOSPHATE GLUCOSE;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENOTOXICITY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ENZYMES; HUMANS; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS;

INSECTA; MAMMALIA;

EID: 0030725269     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. H. J. Barnes, M. P. Arlotto, and M. R. Waterman: Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. USA 88, 5597-5601 (1991).
2. T. H. Richardson, M. Hsu, T. Kronbach, H. J. Barnes, G. Chan, M. R. Waterman, B. Kemper, and E. F. Johnson: Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli: 2C3 encodes the 6ß-hydroxylase-deficient form of P450 3b. Arch. Biochem. Biophys. 300, 510-516 (1993).
3. Y. C. Li and J. Y. L. Chiang: The expression of a catalytically active cholesterol 7α-hydroxylase cytochrome P450 in Escherichia coli. J. Biol. Chem. 266, 19186-19191 (1991).
4. T. H. Richardson, F. Jung, K. J. Griffin, M. Wester, J. L. Raucy, B. Kemper, L. M. Bornheim, C. Hassett, C. J. Omiecmski, and E. F. Johnson: Universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys. 323, 87-96 (1995).
5. J. S. Dong and T. D. Porter: Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Arch. Biochem. Biophys. 327, 254-259 (1996).
6. M. S. Shet, C. W. Fisher, and R. W. Estabrook: The function of recombinant cytochrome P450s in intact Escherichia coli cells: the 17α-hydroxylation of progesterone and pregnenolone by P450c17. Arch. Biochem. Biophys. 339, 218-225 (1997).
7. J. A. R. Blake, M. Pritchard, S. H. Ding, G. C. M. Smith, B. Burchell, C. R. Wolf, and T. Friedberg: Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett. 397, 210-214 (1996).
8. 5 at 2.8 Å resolution. Nature 233, 15-16 (1971).
9. S. Djordjevic, D. L. Roberts, M. Wang, T. Shea, M. G. W. Camitta, B. S. S. Masters, and J. J. P. Kim: Crystallization and preliminary x-ray studies of NADPH-cytochrome P450 reductase. Proc. Natl. Acad. Sci. USA 92, 3214-3218 (1995).
10. C. von Wachenfeldt and E. F. Johnson: Structures of eukaryotic cytochrome P450 enzymes. In "Cytochrome P450: Structure, Mechanism, and Biochemistry" (P. R. Ortiz de Montellano, ed.), 2nd ed., pp. 183-244. Plenum Press, New York, 1995.
11. c17 lacking its hydrophobic amino-terminal signal anchor. Arch. Biochem. Biophys. 304, 272-278 (1993).
12. 2-terminal region on localization in cytosol and membranes. Proc. Natl. Acad. Sci. USA 90, 2651-2655 (1993).
13. U. Scheller, R. Kraft, K.-L. Schröder, and W.-H. Schunck: Generation of the soluble and functional cytosolic domain of microsomal cytochrome P450 52A3. J. Biol. Chem. 269, 12779-12783 (1994).
14. C. von Wachenfeldt, T. H. Richardson, J. Cosme, and E. F. Johnson: Microsomal P450 2C3 is expressed as a soluble dimer in Echerichia coli following modifications of its N-terminus. Arch. Biochem. Biophys. 339, 107-114 (1997).
15. T. D. Porter and C. B. Kasper: NADPH-cytochrome P-450 oxidoreduclase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins. Biochemistry 25, 1682-1687 (1986).
16. S. D. Black and M. J. Coon: Structural features of liver microsomal NADPH-cytochrome P-450 reductase: hydrophobic domain, hydrophilic domain, and connecting region. J. Biol. Chem. 257, 5929-5938 (1982).
17. A. Y. H. Lu, K. W. Junk, and M. J. Coon: Resolution of the cytochrome P-450-containing ω-hydroxylation system of liver microsomes into three components. J. Biol. Chem. 244, 3714-3721 (1969).
18. C. W. Fisher, M. S. Shet, D. L. Caudle, C. A. Martin-Wixtrom, and R. W. Estabrook: High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein. Proc. Natl. Acad. Sci. USA 89, 10817-10821 (1992).
19. F. P. Guengerich, M. V. Martin, Z. Guo, and Y-J. Chun: Purification of recombinant human cytochrome P450 enzymes expressed in bacteria. Methods Enzymol. 272, 35-44 (1996).
20. F. P. Guengerich, E. M. J. Gillam, and T. Shimada: New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26, 551-583 (1996).
21. E. M. J. Gillam, Z. Guo, M. V. Martin, C. M. Jenkins, and F. P. Guengerich: Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch. Biochem. Biophys. 319, 540-550 (1995).
22. M-S. Dong, L. C. Bell, Z. Guo, D. R. Phillips, I. A. Blair, and F. P. Guengerich: Identification of retained N-formylmethionine in bacterial recombinant cytochrome P450 proteins with the N-terminal sequence MALLLAVFL. . . : roles of residues 3-5 in retention and membrane topology. Biochemistry 35, 10031-10040 (1996).
23. C. M. Jenkins and M. R. Waterman: Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J. Biol. Chem. 269, 27401-27408 (1994).
24. M-S. Dong, H. Yamazaki, Z. Guo, and F. P. Guengerich: Recombinant human cytochrome P450 1A2 and an N-terminal truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 327, 11-19 (1996).
25. H. Murakami, Y. Yabusaki, T. Sakaki, M. Shibata, and H. Ohkawa: A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase. DNA 6, 189-197 (1987).
26. Y-J. Chun, T. Shimada, and F. P. Guengerich: Construction of a human cytochrome P450 1A1:rat NADPH-cytochrome P450 reductase fusion protein cDNA, expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification. Arch. Biochem. Biophys. 330, 48-58 (1996).
27. A. Parikh and F. P. Guengerich: Expression, purification,and characterization of a catalytically active human cytochrome P450 1A2:N ADPH-cytochrome P450 reductase fusion protein. Protein Expr. Purif. 9, 346-354 (1997).
28. Y-F. Ueng, T. Kuwabara, Y-J. Chun, and F. P. Guengerich: Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381 (1997).
29. A. Parikh, E. M. J. Gillam, and F. P. Guengerich: Drug metabolism by Escherichia coli expressing human cytochromes P450. Nature Biotechnol., 15, 784-788 (1997).
30. B. N. Ames, W. E. Durston, E. Yamasaki, and F. D. Lee. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA 70, 2281-2285 (1973).
31. R. Thier, S. E. Pemble, J. B. Taylor, W. G. Humphreys, M. Persmark, B. Ketterer, and F. P. Guengerich: Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc. Natl. Acad. Sci. USA 90, 8576-8580 (1993).
32. Y. Oda, H. Yamazaki, R. Thier, B. Ketterer, F. P. Guengerich, and T. Shimada: A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5-5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system. Carcinogenesis (Lond.) 17, 297-302 (1996).
33. T. Shimada, H. Yamazaki, Y. Oda, A. Hiratsuka, T. Watabe, and F. P. Guengerich: Activation and inactivation of carcinogenic dihaloalkanes and other compounds by glutathione S-transferase 5-5 in Salmonella typhimurium tester strain NM5004. Chem. Res. Toxicol. 9, 333-340 (1996).
34. R. Thier, S. Pemble, H. Kramer, J. B. Taylor, F. P. Guengerich, and B. Ketterer: Human glutathione S-transferase T1-1 enhances mutagenicity of 1,2-dibromoethane, dibromomethane, and 1,2,3,4-diepoxybutane in Salmonella typhimurium. Carcinogenesis (Lond.) 17, 163-166 (1996).
35. P. D. Josephy, L. S. DeBruin, H. L. Lord, J. Oak, D. H. Evans, Z. Guo, M-S. Dong, and F. P. Guengerich: Bioactivation of aromatic amines by recombinant human cytochrome P450 1A2 expressed in bacteria: a substitute for mammalian tissue preparations in mulagenicity testing. Cancer Res. 55, 799-802 (1995).
36. T. Shimada, Y. Oda, H. Yamazaki, M. Mimura, and F. P. Guengerich: SOS function tests for studies of chemical carcinogenesis in Salmonella typhimurium TA 1535/pSK1002, NM2009, and NM3009. In "Methods in Molecular Genetics, vol. 5: Gene and Chromosome Analysis" (K. W. Adolph, ed.). pp. 342-355, Academic Press, Orlando, 1994.
37. B. Burchell, D. W. Nebert, D. R. Nelson, K. W. Bock, T. Iyanagi, P. M. Jansen, D. Lancet, G. J. Mulder, J. R. Chowdhury, G. Siest, T. R. Tephly, and P. I. Mackenzie: The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol. 10, 487-494 (1991).
38. N. Moghrabi, L. Sutherland, R. Wooster, S. Povey, M. Boxer, and B. Burchell: Chromosomal assignment of human phenol and bilirubin UDP glucuronosyltransferase genes (UGT1A-subfamily). Ann. Hum. Genet. 56, 81-91 (1992).
39. G. Monaghan, S. Povey, B. Burchell, and M. Boxer: Localization of a bile acid UDP-glucuronosyltransferase gene (UGT2B) to chromosome 4 using the polymerase chain reaction. Genomics 13, 908-909 (1992).
40. R. Wooster, L. Sutherland, T. Ebner, D. Clarke, O: Da Cruz e Silva, and B. Burchell: Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family. Biochem. J. 278, 465-469 (1991).
41. Coffman, B. L., M. D. Green, C. D. King, and T. R. Tephly: Cloning and stable expression of a cDNA encoding a rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 1.1) that catalyzes the glucuronidation of opioids and bilirubin. Mol. Pharmacol. 47, 1101-1105 (1995).
42. N. Nguyenand R. H. Tukey: Baculovirus-directed expression of rabbit UDP-Elucuronosyltransferases in Spodoptera frugiperda cells. Drug Metab. Dispos., 25, 745-749 (1997).
43. T. Philipp, M. Durazzo, C. Trautwein, B. Alex, P. Straub, J. G. Lamb, E. F. Johnson, R. H. Tukey, and M. P. Manns. LKM-3 autoantibodies in chronic hepatitis D recognize the UDP-glucuronosyltransferases. Lancet 344, 578-581 (1994).
44. C. P. Strassburg, P. Obermayer-Straub, B. Alex, M. Durazzo, M. Rizzetto, R. H. Tukey, and M. P. Manns: Autoantibodies against glucuronosyltransferases differ between viral and autoimmune hepatitis. Gastroenterology 111, 1576-1586 (1996).
45. C. P. Strassburg, K. Oldhafer, M. P. Manns, and R. H. Tukey: Differential expression of the UGT1A locus in human liver, biliary and gastric tissue. Identification of UGT1A7 and UGT1A10 transcripts in extra-hepatic tissue. Mol. Pharmacol., in press.
46. B. Burchell, C. H. Brierley, and D. Rance. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57, 1819-1831 (1995).
47. B. Burchell, K. McGurk, C. H. Brierley, and D. J. Clarke: UDP-glucuronosyltransferases. In "Comprehensive Toxicology, vol 3: Biotransformation" (F. P. Guengerich, ed.) pp. 401-435. Pergamon Elsevier, New York, 1997.
48. G. J. Dutton: "Glucuronidation of Drugs and Other Compounds." CRC Press, Boca Raton, 1980.
49. T. Ebner and B. Burchell: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos. 21, 50-55 (1993).
50. D. Harding, S. Fournel-Gigleux, M. R. Jackson, and B. Burchell: Cloning and substrate specificity of a human phenol UDP-glucuronyosyltransferase expressed in COS-7 cells. Proc. Natl. Acad. Sci. USA 85, 8381-8385 (1988).
51. K. A. McGurk, R. P. Remmel, V. P. Hosagrahara, D. Tosh, and B. Burchell: Reactivity of mefenaemic acid 1-O-acetylglucuronide with proteins in vitro and ex vivo. Drug Metab. Dispos. 24, 842-849 (1996).
52. M. Ouzzine, S. Fournel-Gigleux, T. Pillot, B. Burchell, G. Siest, and J. Magdalou: Expression of the human UDP-glucuronosyltransferase UGT1*6 in Escherichia coli: influence of bacterial signal peptides on the production and localization of the recombinant protein. FEBS Lett. 339, 195-199 (1994).
53. M. Ouzzine, T. Pillot, S. Fournel-Gigleux, J. Magdalou, B. Burchell, and G. Siest: Expression and role of the human liver UDP-glucuronosyltransferase UGT1*6 analyzed by specific antibodies raised against a hybrid protein produced in Escherichia coli. Arch. Biochem. Biophys. 310, 196-204 (1994).
54. T. Pillot, M. Ouzzine, S. Fournel-Gigleux, C. Lafaurie, A. Radominska, B. Burchell, G. Siest, and J. Magdalou: Glucuronidation of hyodeoxychoic acid in human liver: evidence for a selective role for UDP-glucuronosyltransterase 2B4. J. Biol. Chem. 268, 25636-25642 (1993).
55. C. Senay, B. Burchell, and S. Fournel-Gigleux: Arginine 52 and histidine 54 located in a conserved N-terminal hydrophic region are important amino acids for the functional and structural integrity of UDP-glucuronosyltransferase 1A6. Mol. Pharmacol. 51, 406-413 (1996).